 Connection
Jesse Schold to Immunosuppressive Agents
This is a "connection" page, showing publications Jesse Schold has written about Immunosuppressive Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.196 |
|
|
|
-
Schold JD, Santos A, Rehman S, Magliocca J, Meier-Kriesche HU. The success of continued steroid avoidance after kidney transplantation in the US. Am J Transplant. 2009 Dec; 9(12):2768-76.
Score: 0.253
-
O'Connell PJ, Kuypers DR, Mannon RB, Abecassis M, Chadban SJ, Gill JS, Murphy B, Nickerson PW, Schold JD, Stock PG, Seron D, Alloway RR, Bromberg JS, Budde K, Jordan SC, Legendre C, Lefaucheur C, Sarwall M, Segev DL, Stegall MD, Tullius SG, Wong G, Woodle ES, Ascher N, Morris RE. Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction. Transplantation. 2017 07; 101(7):1527-1534.
Score: 0.108
-
Koyawala N, Silber JH, Rosenbaum PR, Wang W, Hill AS, Reiter JG, Niknam BA, Even-Shoshan O, Bloom RD, Sawinski D, Nazarian S, Trofe-Clark J, Lim MA, Schold JD, Reese PP. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation. J Am Soc Nephrol. 2017 Jul; 28(7):2188-2200.
Score: 0.106
-
Schold J, Poggio E, Goldfarb D, Kayler L, Flechner S. Clinical outcomes associated with induction regimens among retransplant kidney recipients in the United States. Transplantation. 2015 Jun; 99(6):1165-71.
Score: 0.093
-
Schold JD, Buccini LD, Goldfarb DA, Flechner SM, Hsich E, Mason D, Fung J, Stephany BR, Krishnamurthi V, Srinivas TR. Patient participation in research among solid organ transplant recipients in the United States. Transplantation. 2011 Jun 27; 91(12):1424-35.
Score: 0.071
-
Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant. 2012 Feb; 27(2):850-7.
Score: 0.071
-
Schold JD, Kaplan B. AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. Am J Transplant. 2009 Sep; 9(9):2067-74.
Score: 0.062
-
Kayler LK, Garzon P, Magliocca J, Fujita S, Kim RD, Hemming AW, Howard R, Schold JD. Outcomes and utilization of kidneys from deceased donors with acute kidney injury. Am J Transplant. 2009 Feb; 9(2):367-73.
Score: 0.060
-
Srinivas TR, Schold JD, Guerra G, Eagan A, Bucci CM, Meier-Kriesche HU. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant. 2007 Mar; 7(3):586-94.
Score: 0.052
-
Srinivas TR, Kaplan B, Schold JD, Meier-Kriesche HU. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation. 2005 Oct 15; 80(2 Suppl):S211-20.
Score: 0.048
-
Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant. 2005 Sep; 5(9):2273-80.
Score: 0.047
-
Kaplan B, Schold J, Srinivas T, Womer K, Foley DP, Patton P, Howard R, Meier-Kriesche HU. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant. 2004 Oct; 4(10):1709-12.
Score: 0.045
-
Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol. 2003 Nov; 14(11):2980-4.
Score: 0.042
-
Braun WE, Herlitz L, Li J, Schold J, Poggio E, Stephany B, Fatica R, Nally J, Brown K, Fairchild R, Baldwin W, Goldfarb D, Kiser W, Augustine J, Avery R, Tomford JW, Nakamoto S. Continuous function of 80 primary renal allografts for 30-47 years with maintenance prednisone and azathioprine/mycophenolate mofetil therapy: A clinical mosaic of long-term successes. Clin Transplant. 2021 01; 35(1):e14131.
Score: 0.034
-
Cravedi P, Schold JD, Safa K, Kates OS, Elfadawy N, Mannon RB, Shah MB, Hammond SP, Avery R, Guerrero Miranda C, Riella LV, Jowsey-Gregoire S, Akalin E, Camirand G, Alegre ML, Azzi J. The COVID-19 pandemic: A community approach. Clin Transplant. 2020 11; 34(11):e14059.
Score: 0.034
-
Elfadawy N, Flechner SM, Schold JD, Srinivas TR, Poggio E, Fatica R, Avery R, Mossad SB. Transient versus persistent BK viremia and long-term outcomes after kidney and kidney-pancreas transplantation. Clin J Am Soc Nephrol. 2014 Mar; 9(3):553-61.
Score: 0.021
-
Elfadawy N, Flechner SM, Liu X, Schold J, Srinivas TR, Poggio E, Fatica R, Avery R, Mossad SB. CMV Viremia is associated with a decreased incidence of BKV reactivation after kidney and kidney-pancreas transplantation. Transplantation. 2013 Dec 27; 96(12):1097-103.
Score: 0.021
-
Scornik JC, Schold JD, Bucci M, Meier-Kriesche HU. Effects of blood transfusions given after renal transplantation. Transplantation. 2009 May 15; 87(9):1381-6.
Score: 0.015
-
Scornik JC, Guerra G, Schold JD, Srinivas TR, Dragun D, Meier-Kriesche HU. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant. 2007 Jul; 7(7):1808-14.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|